BsAbs generally have acceptable side effects; for example, preclinical studies have shown that ABL503 (PD-1 × 4-1BB) is well tolerated with a low risk of liver toxicity and superior activity compared to a combination of the corresponding monoclonal antibodies (27). The gene discussed is PDCD1; the disease is toxicity.